Dose Response to Recombinant Factor VIIa When Administered for Bleed

Novo Nordisk A/S64 enrolled

Overview

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Congenital Bleeding Disorder Healthy

Interventions

activated recombinant human factor VIIDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ages Eligible for Study: 18 Years - 60 Years Exclusion Criteria: * \- -

Locations (1)

Novo Nordisk Investigational Site

Overland Park, Kansas, United States

Outcomes

Primary Outcomes

Dose Response to Recombinant Factor VIIa

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.